177lu-psma-r2
Small moleculeexperimental
Clinical trial activity
12 trials · 18 clinical orgs · 0 marketing orgs
Phase 1
8
Phase 2
10
Phase 3
1
Phase 4
0
Earliest trial started May 23, 2018 (NCT03490032)
Timeline
Indications
Mechanism of action
- Glutamate carboxypeptidase IIBINDING AGENT
FOLH1 binding agent
- Unspecified targetRadiodepletion
radiodepletion
Chemistry & pharmacology
- Payload
- 177-lutetium
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07310355 | Phase 1/Phase 2 (Phase 2) | Dec 30, 2025 | Government of China |
| NCT06343038 | Phase 1 | Feb 20, 2024 | University of Basel |
| NCT05896371 | Phase 1/Phase 2 (Phase 2) | Jan 29, 2024 | Canadian Institutes of Health Research (CIHR), Laval University |
| NCT06059014 | Phase 1/Phase 2 (Phase 2) | Nov 9, 2023 | Centre Leon Berard |
| NCT06050239 | Early Phase 1 (Phase 1) | Mar 1, 2023 | Nanjing Medical University |
| NCT05383079 | Phase 1/Phase 2 (Phase 2) | Sep 13, 2022 | Peter MacCallum Cancer Centre |
| NCT05204927 | Phase 3 | Feb 14, 2022 | Curium Pharma |
| NCT04419402 | Phase 2 | Jun 1, 2020 | Astellas, Australian and New Zealand Urogenital and Prostate Cancer Trials Group, Australian Nuclear Science and Technology Organisation, Endocyte, Government of Australia, Prostate Cancer Research Alliance, University of New South Wales |
| NCT04291300 | Phase 2 | May 1, 2020 | Dutch Cancer Society, Radboud University |
| NCT04188587 | Phase 2 | Jan 1, 2019 | Nanjing Medical University |
| NCT03490838 | Phase 1/Phase 2 (Phase 2) | May 24, 2018 | Advanced Accelerator Applications |
| NCT03490032 | Phase 1/Phase 2 (Phase 2) | May 23, 2018 | Advanced Accelerator Applications |
Showing 12 of 12 trials
Page 1 / 1
Organizations
Research & Development (18)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Advanced Accelerator Applications | For profit | 2 | 2 | 1 | 2018 |
| Nanjing Medical University | Academic/Hospital | 2 | 2 | 2 | 2019 |
| Astellas | For profit | 1 | 0 | 1 | 2020 |
| Australian and New Zealand Urogenital and Prostate Cancer Trials Group | Academic/Hospital | 1 | 1 | 1 | 2020 |
| Australian Nuclear Science and Technology Organisation | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Canadian Institutes of Health Research (CIHR) | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Centre Leon Berard | Academic/Hospital | 1 | 1 | 1 | 2023 |
| Curium Pharma | For profit | 1 | 1 | 1 | 2022 |
| Dutch Cancer Society | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Endocyte | For profit | 1 | 0 | 1 | 2020 |
| Government of Australia | Government | 1 | 0 | 1 | 2020 |
| Government of China | Government | 1 | 1 | 1 | 2025 |
| Laval University | Academic/Hospital | 1 | 1 | 1 | 2024 |
| Peter MacCallum Cancer Centre | Academic/Hospital | 1 | 1 | 1 | 2022 |
| Prostate Cancer Research Alliance | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Radboud University | Academic/Hospital | 1 | 1 | 1 | 2020 |
| University of Basel | Academic/Hospital | 1 | 1 | 1 | 2024 |
| University of New South Wales | Academic/Hospital | 1 | 0 | 1 | 2020 |
18 organizations
Page 1 / 1